SEC Form 4 · accession 0001398595-26-000004
ARS Pharmaceuticals, Inc. · SPRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander A Fitzpatrick
Officer — Chief Legal Officer
Period of report
Jun 12, 2026
Accepted (ET)
Jun 12, 2026 · 8:04 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001671858
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 12, 2026 | S | 3,355 | $10.00 | D | 90,910 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
- F2Includes 2,907 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2025 and 1,745 shares acquired under the ESPP on December 31, 2025.